Rimonabant’s Feeding Effect Faded While Lower Body Weight Persisted in Rats
In a rat study, tolerance to rimonabant's food-intake suppression developed within five days, but treated animals remained lighter than controls throughout two weeks. Feeding response and body-weight difference followed different trajectories.
The experiment involved a CB1-blocking drug
Adult non-obese Wistar rats received daily injected SR141716, commonly called rimonabant. Food intake and body weight decreased in a dose-dependent manner initially. This was not a study administering THC, and it should not be described as an appetite effect of marijuana itself.
Weight is a cumulative outcome
Loss of the ongoing intake-suppression effect did not require body weight to immediately catch up with controls. A persisting weight gap can reflect earlier changes and other unmeasured influences. The abstract does not establish which mechanism maintained the difference, so it cannot be used to assert a demonstrated metabolic explanation.
Tolerance must name the measured endpoint
The authors reported tolerance to the anorectic effect, meaning reduced suppression of eating. That is different from proving tolerance to all drug effects or disappearance of every downstream consequence. The 14-day observation period also does not show what happened over longer exposure or after treatment ended.
The study supports involvement of cannabinoid receptors in appetite and weight regulation while illustrating an important timing distinction. It does not establish a current treatment recommendation, a human weight-loss expectation or a safe dosing regimen. Immediate behavior and accumulated physiological outcomes require separate interpretation.
Related: interpreting cannabis tolerance claims.
Research cited
Colombo G; Agabio R; Diaz G; Lobina C; Reali R; Gessa GL. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life sciences (1998). doi:10.1016/s0024-3205(98)00322-1. Findings discussed from the study abstract.
